Compare RELL & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | SLGL |
|---|---|---|
| Founded | 1947 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 268.9M |
| IPO Year | 2004 | 2016 |
| Metric | RELL | SLGL |
|---|---|---|
| Price | $19.88 | $84.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 358.7K | 36.4K |
| Earning Date | 04-08-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $228,564,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | $223.84 |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 9.41 | N/A |
| 52 Week Low | $9.37 | $14.78 |
| 52 Week High | $23.15 | $97.97 |
| Indicator | RELL | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 54.50 |
| Support Level | $15.05 | $67.53 |
| Resistance Level | $23.15 | $94.33 |
| Average True Range (ATR) | 1.73 | 6.10 |
| MACD | 0.20 | 0.14 |
| Stochastic Oscillator | 50.30 | 44.23 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.